Weight Loss Drug Zepbound from Eli Lilly Shown to Significantly Reduce Sleep Apnea Events in Adults with Obesity
Indianapolis, IN – Eli Lilly’s weight loss drug, Zepbound, has shown promising results in reducing obstructive sleep apnea in adults with obesity, according to a recent announcement by the drugmaker. Obstructive sleep apnea, a condition affecting approximately 39 million adults in the U.S., occurs when a person’s upper airway becomes blocked during sleep, leading to disruptions in airflow throughout the night. The National Heart, Lung, and Blood Institute states that obesity, by narrowing the airway, …